Skip to content

Ketamine: all studies

Page 369 of 449: studies 3,681 to 3,690 of 4,486, newest first. Back to the ketamine overview

Research

Digital Enablement of Psychedelic-Assisted Therapy in Non-Clinical Settings: A Systematic Review of Safety, Efficacy, and Implementation Models

Psychoactives December 24, 2025 Brendan Driscoll, Shaheen E. Lakhan 1 citation

Psychedelic-assisted therapy offers rapid and profound benefits for treatment-resistant psychiatric conditions but remains constrained by the need for intensive, clinic-based administration. Concurrently, advances in digital health technologies have introduced scalable tools. This systematic review evaluates the safety, efficacy, and implementation of digitally enabled psychedelic-assisted...

“Tragic Person evolved: Transforming tragedy into hope through new, alternative treatments”

Psychoanalysis Self and Context December 22, 2025 Douglas Zimmerman

The paper, “Tragic Person Evolved: Transforming Tragedy Into Hope Through New, Alternative Treatments” was presented at the 45th IAPSP International Conference in Rome in October of 2024. The paper explores the integration of relational psychoanalysis and alternative treatments, including ketamine-assisted psychotherapy, for individuals with OCD, ADHD, and ASD. Two case studies illustrate how...

DOI: 10.1080/24720038.2025.2604803 (opens in new tab) Tragedy event Criticism Action physics Field mathematics +2

Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment

˜The œjournal of desk research review and analysis. December 16, 2025 M. H. M. Wickramasekara, G. D. M. C. Gonapaladeniya

Psychedelic-assisted therapy (PAT) has emerged as a promising and innovative approach to treating a range of mental health disorders, including depression, post-traumatic stress disorder (PTSD), and substance use disorders. Once sidelined due to regulatory bans and social stigma, psychedelics such as psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and...

Towards therapeutic paths with mindfulness meditation–based and psychedelics assisted psychotherapies in PTSD: Randomized controlled trials systematic review and meta-analysis

Cortica December 15, 2025 Solène Maeder, Cherine Fahim, Chantal Martin-Soelch

The purpose of this study was to compare mindfulness meditation-based interventions (MMBIs) and psychedelic-assisted psychotherapies (PAP) in PTSD and examine altered-state mediators as a shared mechanism. Following PRISMA 2020 guidelines, PubMed, Web of Science, and EBSCOhost were systematically searched for randomized controlled trials (RCTs) published through January 2024. Trials reporting...

DOI: 10.26034/cortica.2025.8925 (opens in new tab) Mindfulness Randomized controlled trial Psychological intervention Intervention counseling +9

Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation

Molecular Neurobiology December 10, 2025 Ying Wei, Xiang Liu, Shijun Lin et al.

Schizophrenia (SCZ), a chronic psychiatric disorder, is characterized by cognitive impairment, hallucinations, and delusions, with current antipsychotic treatments offering limited efficacy and considerable side effects. Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, has shown promise in treating neurological and psychiatric conditions, though its precise mechanisms in...

Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial.

NPJ Digital Medicine December 8, 2025 Joseph Geraci, Bessi Qorri, Mike Tsay et al.

Clinical trial failures are frequently driven by patient heterogeneity and limited sample sizes that obscure treatment effects by diluting statistical power. We introduce NetraAI, a novel explainable artificial intelligence (AI) platform that integrates dynamical-systems modeling, evolutionary long-range memory feature selection, and large-language model (LLM)-generated insights, to discover...

Rapid Mood Improvement and Transient Hypomania After Low-Dose Oral OTC Glutamatergic Augmentation in Post-TBI Bipolar Disorder

Preprints.org December 5, 2025 Ngo Cheung preprint

Background: Bipolar disorder secondary to traumatic brain injury (TBI) is common, mechanistically distinct, and notoriously treatment-resistant. Rapid-acting glutamatergic antidepressants such as ketamine are effective in bipolar depression but remain inaccessible to most patients.Case presentation: We describe a woman in her mid-thirties with documented right frontal atrophy after a severe...

DOI: 10.20944/preprints202512.0486.v1 (opens in new tab) Hypomania Bipolar disorder Dextromethorphan Bipolar ii disorder +7

Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges

Advanced Neurology December 4, 2025 Taslim Uddin, Sharmin Akter, Kaustabh Ghosh

Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disorders. Psilocybin, lysergic acid diethylamide, N,N-dimethyltryptamine, and ketamine are substances that mainly affect the serotonergic and glutamatergic systems. They induce rapid synaptogenesis, dendritic remodeling, and changes in functional...

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.

Therapeutic Advances in Psychopharmacology December 4, 2025 Charles Dodds, Rachelle Dawson, Alexander Lim et al. 3 citations

Novel interventions for post-traumatic stress disorder (PTSD) leverage the psychoactive properties of psychedelic compounds, such as ketamine, 3,4-methylenedioxymethamphetamine and psilocybin, which may overcome limitations of conventional treatments. Through the modulation of pathways involved in synaptic plasticity, psychedelic interventions are believed to enhance the mechanisms underlying...

Defining ‘psychedelic’

December 4, 2025 Avery Ostrand, Matthew M. Nour, Christopher Timmermann et al. 2 citations preprint

Humphry Osmond coined the term ‘psychedelic’ in 1956, conjoining ‘psyche’ for ‘soul’ and ‘delic’ from ‘dêlos’ for ‘to manifest’ or ‘illuminate.’ Soul-illumination is an adjective that describes a psychological state or process. However, Osmond’s intention was to use the adjective to name— not just a state— but a category of drug that can induce the subjective effect as its principal action;...